Ciprofloxacin
(Synonyms: 环丙沙星; Bay-09867) 目录号 : GC13550
Ciprofloxacin (Bay-09867) 是一种有效的、具有口服活性的拓扑异构酶 IV 抑制剂。
Cas No.:85721-33-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
Bacterial inocula are prepared by suspending colonies into Mueller-Hinton broth (CAMHB) (containing Ciprofloxacin) from 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) on sheep blood agar (SBA) plates that are incubated at 35°C. Suspended cultures are diluted with CAMHB to a bacterial cell density of 105 CFU/mL adjusted based on the optical density at 600 nm. To each well of the 96-well plate, 50 μL of dilutions is added for a final inoculum of ~5×104 CFU/well. Plates are incubated at 35°C. MICs are determined visually at 18 to 24 h (B. anthracis) or 42 to 48 h (Y. pestis) and also by absorbance at 600 nm[2]. |
|
Animal experiment: |
Female BALB/cAnNCrl (BALB/c) mice, 8 to 10 weeks old and 20 g (±4 g) are used in this assay. A single dose of Ciprofloxacin (Bay-09867) (30 mg/kg) is administered to mice (n=30) via the intraperitoneal (i.p.) route. The mice (n=3/time point/group) are culled at 1, 10, 20, or 30 min and 1, 1.5, 2, 4, 8, 12 h following Ciprofloxacin administration and 1, 15, or 30 min and 1, 2, 4, 6, 10, 18, or 24 h following DRCFI or CFI administration. Blood sampling points are chosen based upon the short half-life of Ciprofloxacin and longer half-life of CFI. Blood and lungs (whole organ) are collected post mortem for analysis. The lung doses following CFI or DRCFI administration are calculated using the concentration of Ciprofloxacin in the lung samples at 1 min post-administration[3]. |
|
References: [1]. Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4. pii: S1382-6689(17)30029-7 |
|
Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.
Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1]. Ciprofloxacin (CIP) shows potent activity against Y. pestis with MIC90 of 0.03 μg/mL[2].
Ciprofloxacin (Bay-09867) (1 mg/L) induces glutathione-S-transferase (GST) activity, in contrast with inhibited GST and Catalase (CAT) of larvae exposed to enrofloxacin. Ciprofloxacin (Bay-09867) (≥10 μg/L) and enrofloxacin are ecotoxic for development, growth, detoxifying, and oxidative stress enzymes in anuran amphibian larvae[1]. In a murine model of pneumonic plague, Ciprofloxacin (Bay-09867) (30 mg/kg, i.p.) results in a drug exposure which is similar to the drug exposure observed in human following a 500 mg dose of oral Ciprofloxacin (Bay-09867). Intraperitoneal Ciprofloxacin (Bay-09867) reduces the lung bacterial load compare to controls treated with intraperitoneal PBS[3].
Reference:
[1]. Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4. pii: S1382-6689(17)30029-7
[2]. Steenbergen J, et al. In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Feb 21.
[3]. Hamblin KA, et al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.
| Cas No. | 85721-33-1 | SDF | |
| 别名 | 环丙沙星; Bay-09867 | ||
| 化学名 | 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid | ||
| Canonical SMILES | C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O | ||
| 分子式 | C17H18FN3O3 | 分子量 | 331.34 |
| 溶解度 | 0.1 M HCL : 16.67 mg/mL (50.31 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C) ; H2O : < 0.1 mg/mL (insoluble) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.018 mL | 15.0902 mL | 30.1805 mL |
| 5 mM | 0.6036 mL | 3.018 mL | 6.0361 mL |
| 10 mM | 0.3018 mL | 1.509 mL | 3.018 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。